definiens: shall mean the use of [COMPANY] Poloxamer Intellectual Property in polynucleotide -based therapeutics and prophylactics ( including DNA, RNA, viral, and all other biologically active natural and synthetic polynucleotides such as antisense ( includ ing antisense polynucleotides containing phosphothioester moieties ) and CpG materials ) alone or in combination with a protein or peptide antigen as part of a prime / boost regime, for all human and animal health applications, except for the following : a ) those fields of use currently licensed to Merck, as described in the Merck License, b ) DNA vaccines and / or therapeutics based on PSMA ( as defined in Section 1.17 hereof ), c ) sale of a non -regula ted product for use as a non -clinical research reagent to increase transfection in vitro or in laboratory animals